![]() ![]() “We are confident that we will prevail in this action and achieve our goals of increasing patient access, introducing competition and offering biosimilar products at prices competitive with and lower than those maintained by Amgen and other large pharmaceutical companies. This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this Agreement) is entered into as of Decem(the Signing Date) by and between AMGEN INC. With approval supplement on deck, Reata dives into launch of its first commercial. “Coherus remains committed to the important goal of bringing much-needed biosimilar drugs to the marketplace,” said CEO Denny Lanfear in a statement. RESEARCH COLLABORATION AND LICENSE AGREEMENT. Risk Management for Headquarters and R&D Sites at Amgen Inc. Activist investor NexPoint threatens to block Parateks 462M sale. And the Redwood City, CA-based Coherus says it plans to defend itself vigorously, adding that Amgen is solely interested in fending off competition to pegfilgrastim by mounting a delaying action in state court. →Amgen $AMGN has filed a lawsuit against Coherus BioSciences $CHRS claiming theft of trade secrets, according to a statement from the biotech. Amgen is swooping in on a hot new cancer therapy, announcing Monday that it will partner with Kite Pharma on a strategic research and licensing collaboration worth an initial 60 million to develop and commercialize novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite 's engineered autologous cell therapy (eACT) platform. ![]() → Richard Wang, the former site chief for GSK in Shanghai, is taking the CEO’s job at Fosun Kite, a joint venture established by Kite Pharma and Shanghai Fosun to advance Kite’s CAR-T $KITE to the market. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |